Findings of Scientific Misconduct, 75119-75120 [E8-29203]

Download as PDF Federal Register / Vol. 73, No. 238 / Wednesday, December 10, 2008 / Notices (NIOSH), Department of Health and Human Services (HHS). ACTION: Notice. 2008, as provided for under 42 U.S.C. 7384q(b), the Secretary of HHS designated the following class of employees as an addition to the SEC: SUMMARY: The Department of Health and Human Services (HHS) gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees at the Vitro Manufacturing in Canonsburg, Pennsylvania, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation Program Act of 2000. The initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows: Facility: Vitro Manufacturing. Location: Canonsburg, Pennsylvania. Job Titles and/or Job Duties: All Atomic Weapons Employer employees. Period of Employment: August 13, 1942 through December 31, 1957. FOR FURTHER INFORMATION CONTACT: Larry Elliott, Director, Office of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 513– 533–6800 (this is not a toll-free number). Information requests can also be submitted by e-mail to OCAS@CDC.GOV. This designation became effective on November 23, 2008, as provided for under 42 U.S.C. 7384l(14)(C). Hence, beginning on November 23, 2008, members of this class of employees, defined as reported in this notice, became members of the Special Exposure Cohort. FOR FURTHER INFORMATION CONTACT: Larry Elliott, Director, Office of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 513– 533–6800 (this is not a toll-free number). Information requests can also be submitted by e-mail to OCAS@CDC.GOV. Dated: December 4, 2008. Christine M. Branche, Acting Director, National Institute for Occupational Safety and Health. [FR Doc. E8–29244 Filed 12–9–08; 8:45 am] Dated: December 5, 2008. Christine M. Branche, Acting Director, National Institute for Occupational Safety and Health. [FR Doc. E8–29246 Filed 12–9–08; 8:45 am] BILLING CODE 4163–19–P BILLING CODE 4163–19–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute for Occupational Safety and Health Office of the Secretary Findings of Scientific Misconduct Final Effect of Designation of a Class of Employees for Addition to the Special Exposure Cohort mstockstill on PROD1PC66 with NOTICES AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. SUMMARY: The Department of Health and Human Services (HHS) gives notice concerning the final effect of the HHS decision to designate a class of employees at Connecticut Aircraft Nuclear Engine Laboratory in Middletown, Connecticut, as an addition to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000. On October 24, VerDate Aug<31>2005 16:49 Dec 09, 2008 Jkt 217001 All employees of the Department of Energy (DOE), its predecessor agencies, and DOE contractors or subcontractors who worked at the Connecticut Aircraft Nuclear Engine Laboratory in Middletown, CT, from January 1, 1958 through December 31, 1965 for a number of work days aggregating at least 250 work days occurring either solely under this employment or in combination with work days within the parameters established for one or more other classes of employees in the Special Exposure Cohort. AGENCY: Office of the Secretary, HHS. ACTION: Notice. SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Homer D. Venters, Jr., M.D., University of Illinois at UrbanaChampaign: Based on the report of an investigation conducted by the University of Illinois at UrbanaChampaign (UIUC) and extensive additional image analysis conducted by the Office of Research Integrity (ORI), the U.S. Public Health Service (PHS) found that Dr. Homer D. Venters, former graduate student, Neuroscience PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 75119 Program, UIUC, engaged in scientific misconduct in research supported by National Institute of Mental Health (NIMH), National Institutes of Health (NIH), awards R01 MH051569 and F30 MH12558 and National Institute on Aging (NIA), NIH, award R01 AG06246. Specifically, PHS found that the Respondent committed misconduct in science: • By intentionally and knowingly preparing and including duplicate image data in Figures 5 and 10 of PHS fellowship application F31 MH12558, ‘‘Neurodegeneration via TNF-alpha inhibition of IGF–1,’’ submitted in 1999, which was funded as F30 MH12558 from June 1, 2000, to May 31, 2003. Because the duplicate data were labeled as having been obtained from different experiments, the results for at least one of the two figures were intentionally falsified and constitute an act of scientific misconduct. • By intentionally and knowingly preparing and including duplicate image data in Figure 3 and/or 4 of a manuscript submitted and published as: Venters, H.D., et al. ‘‘A New Mechanism of Neurodegeneration: A Proinflammatory Cytokine Inhibits Receptor Signaling by a Survival Peptide.’’ Proceedings of the National Academy of Sciences U.S.A. 96:9879– 9884, 1999. • By preparing and providing to his dissertation committee in March 2000 a thesis proposal entitled ‘‘An Alternate Mechanism of Neurodegeneration: Silencing of Insulin-like Growth FactorI survival signals by Tumor Necrosis Factor-a,’’ which contained five falsified figures: Figures 1.3, 1.4a, 2.1b, 2.3e, and 2.5b. In each figure, he reused data within the same figure or in another thesis proposal figure as representing differently treated samples or as data obtained with different immunoblotting antisera. • In March and April 2001, Respondent included several of the same falsified figures as in the thesis proposal and multiple additional falsified figures in his dissertation ‘‘Silencing of Insulin-like Growth Factor I Neuronal Survival Signals by Tumor Necrosis Factor-a.’’ In all, Figures 3.3, 3.4a, 3.4b, 4.1b, 4.3a, 4.5b, 5.1a, 5.2, 5.4a, 5.5a, 5.6a, 5.7a, and 5.8a were falsified. In each instance, he assembled figures by reusing significant data, on some occasions after manipulating the orientation of the data, either within the same figure or in other figures related to his thesis and represented the data falsely as coming from different samples or different experiments. Dr. Venters has entered into a Voluntary Settlement Agreement E:\FR\FM\10DEN1.SGM 10DEN1 75120 Federal Register / Vol. 73, No. 238 / Wednesday, December 10, 2008 / Notices (Agreement) in which he has voluntarily agreed, for a period of three (3) years, beginning on November 19, 2008: (1) That any institution that submits an application for PHS support for a research project on which the Respondent’s participation is proposed or that uses the Respondent in any capacity on PHS-supported research, or that submits a report of PHS-funded research in which the Respondent is involved, must concurrently submit a plan for monitoring of the Respondent’s research to the funding agency and ORI for approval; the monitoring plan must be designed to ensure the scientific integrity of the Respondent’s research contribution; Respondent agreed that he will not participate in any PHSsupported research until such a monitoring plan is submitted to ORI and the funding agency; (2) That Respondent will ensure that any institution employing him will submit to ORI, in conjunction with each application for PHS funds or report, manuscript, or abstract of PHS-funded research in which the Respondent is involved, a certification that the data provided by the Respondent are based on actual experiments or are otherwise legitimately derived, and that the data analyses, procedures, and methodology are accurately reported in the application or report; Respondent must ensure that the institution sends a copy of each certification to ORI; and (3) To exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant or contractor to PHS. Respondent also voluntarily agreed that within 30 days of the effective date of this Agreement: (4) He will submit a letter to the journal editor, with copies to his coauthors, identifying his falsification of Figures 3 and/or 4 in the following article: Venters et al. ‘‘A New Mechanism of Neurodegeneration: A Proinflammatory Cytokine Inhibits Receptor Signaling by a Survival Peptide.’’ Proceedings of the National Academy of Sciences 96:9879–9884, 1999. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. Chris B. Pascal, Director, Office of Research Integrity. [FR Doc. E8–29203 Filed 12–9–08; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources And Services Administration Agency Information Collection Activities: Proposed Collection: Comment Request In compliance with the requirement for opportunity for public comment on proposed data collection projects (section 3506(c)(2)(A) of Title 44, United States Code, as amended by the Paperwork Reduction Act of 1995, Pub. L. 104–13), the Health Resources and Services Administration (HRSA) publishes periodic summaries of proposed projects being developed for submission to OMB under the Paperwork Reduction Act of 1995. To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, call the HRSA Reports Clearance Officer on (301) 443–1129. Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: Health Centers Patient Survey—(NEW) The Health Center program supports Community Health Centers (CHCs), Migrant Health Centers (MHCs), Health Care for the Homeless (HCH) projects, and Public Housing Primary Care (PHPC) programs. Health Centers (HCs) receive grants from HRSA to provide primary and preventive health care services to medically underserved populations. The proposed Patient Survey will collect in-depth information about HC patients, their health status, the reasons they seek care at HCs, their diagnoses, the services they utilize at HCs and elsewhere, the quality of those services, and their satisfaction with the care they receive, through personal interviews of a stratified random sample of HC patients. Interviews are planned to take approximately 1 hour and six minutes each. The Patient Survey builds on previous periodic User-Visit Surveys which were conducted to learn about the process and outcomes of care in CHCs and HCH projects. The original questionnaires were derived from the National Health Interview Survey (NHIS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS) conducted by the National Center for Health Statistics (NCHS). Conformance with the NHIS and NHAMCS allowed comparisons between these NCHS surveys and the previous CHC and HCH User-Visit Surveys. The new Patient Survey was developed using a questionnaire methodology similar to that used in the past, and will also potentially allow some longitudinal comparisons for CHCs and HCH projects with the previous User-Visit survey data, including monitoring of process outcomes over time. In addition, this survey will include interviews of patients drawn from migrant populations and from residents of public housing, populations not included in the previous surveys. The estimated response burden for the survey is as follows: SURVEY Number of respondents mstockstill on PROD1PC66 with NOTICES Type of respondent; activity involved Responses per respondent Total number of responses Burden per response (hours) Total hour burden Grantee/Site Recruitment and Site Training .. Patient Recruitment ........................................ Patient Survey 4526 ....................................... 115 5658 4526 3 1 1 345 5658 4526 3.75 .167 1.1 1294 945 4979 Total ......................................................... 5773 ............................ 10529 .............................. 7218 VerDate Aug<31>2005 16:49 Dec 09, 2008 Jkt 217001 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\10DEN1.SGM 10DEN1

Agencies

[Federal Register Volume 73, Number 238 (Wednesday, December 10, 2008)]
[Notices]
[Pages 75119-75120]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-29203]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) and the Assistant Secretary for Health have taken final action in 
the following case:
    Homer D. Venters, Jr., M.D., University of Illinois at Urbana-
Champaign: Based on the report of an investigation conducted by the 
University of Illinois at Urbana-Champaign (UIUC) and extensive 
additional image analysis conducted by the Office of Research Integrity 
(ORI), the U.S. Public Health Service (PHS) found that Dr. Homer D. 
Venters, former graduate student, Neuroscience Program, UIUC, engaged 
in scientific misconduct in research supported by National Institute of 
Mental Health (NIMH), National Institutes of Health (NIH), awards R01 
MH051569 and F30 MH12558 and National Institute on Aging (NIA), NIH, 
award R01 AG06246.
    Specifically, PHS found that the Respondent committed misconduct in 
science:
     By intentionally and knowingly preparing and including 
duplicate image data in Figures 5 and 10 of PHS fellowship application 
F31 MH12558, ``Neurodegeneration via TNF-alpha inhibition of IGF-1,'' 
submitted in 1999, which was funded as F30 MH12558 from June 1, 2000, 
to May 31, 2003. Because the duplicate data were labeled as having been 
obtained from different experiments, the results for at least one of 
the two figures were intentionally falsified and constitute an act of 
scientific misconduct.
     By intentionally and knowingly preparing and including 
duplicate image data in Figure 3 and/or 4 of a manuscript submitted and 
published as: Venters, H.D., et al. ``A New Mechanism of 
Neurodegeneration: A Proinflammatory Cytokine Inhibits Receptor 
Signaling by a Survival Peptide.'' Proceedings of the National Academy 
of Sciences U.S.A. 96:9879-9884, 1999.
     By preparing and providing to his dissertation committee 
in March 2000 a thesis proposal entitled ``An Alternate Mechanism of 
Neurodegeneration: Silencing of Insulin-like Growth Factor-I survival 
signals by Tumor Necrosis Factor-[alpha],'' which contained five 
falsified figures: Figures 1.3, 1.4a, 2.1b, 2.3e, and 2.5b. In each 
figure, he reused data within the same figure or in another thesis 
proposal figure as representing differently treated samples or as data 
obtained with different immunoblotting antisera.
     In March and April 2001, Respondent included several of 
the same falsified figures as in the thesis proposal and multiple 
additional falsified figures in his dissertation ``Silencing of 
Insulin-like Growth Factor I Neuronal Survival Signals by Tumor 
Necrosis Factor-[alpha].'' In all, Figures 3.3, 3.4a, 3.4b, 4.1b, 4.3a, 
4.5b, 5.1a, 5.2, 5.4a, 5.5a, 5.6a, 5.7a, and 5.8a were falsified. In 
each instance, he assembled figures by reusing significant data, on 
some occasions after manipulating the orientation of the data, either 
within the same figure or in other figures related to his thesis and 
represented the data falsely as coming from different samples or 
different experiments.
    Dr. Venters has entered into a Voluntary Settlement Agreement

[[Page 75120]]

(Agreement) in which he has voluntarily agreed, for a period of three 
(3) years, beginning on November 19, 2008:
    (1) That any institution that submits an application for PHS 
support for a research project on which the Respondent's participation 
is proposed or that uses the Respondent in any capacity on PHS-
supported research, or that submits a report of PHS-funded research in 
which the Respondent is involved, must concurrently submit a plan for 
monitoring of the Respondent's research to the funding agency and ORI 
for approval; the monitoring plan must be designed to ensure the 
scientific integrity of the Respondent's research contribution; 
Respondent agreed that he will not participate in any PHS-supported 
research until such a monitoring plan is submitted to ORI and the 
funding agency;
    (2) That Respondent will ensure that any institution employing him 
will submit to ORI, in conjunction with each application for PHS funds 
or report, manuscript, or abstract of PHS-funded research in which the 
Respondent is involved, a certification that the data provided by the 
Respondent are based on actual experiments or are otherwise 
legitimately derived, and that the data analyses, procedures, and 
methodology are accurately reported in the application or report; 
Respondent must ensure that the institution sends a copy of each 
certification to ORI; and
    (3) To exclude himself from serving in any advisory capacity to 
PHS, including but not limited to service on any PHS advisory 
committee, board, and/or peer review committee, or as a consultant or 
contractor to PHS.
    Respondent also voluntarily agreed that within 30 days of the 
effective date of this Agreement:
    (4) He will submit a letter to the journal editor, with copies to 
his coauthors, identifying his falsification of Figures 3 and/or 4 in 
the following article: Venters et al. ``A New Mechanism of 
Neurodegeneration: A Proinflammatory Cytokine Inhibits Receptor 
Signaling by a Survival Peptide.'' Proceedings of the National Academy 
of Sciences 96:9879-9884, 1999.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E8-29203 Filed 12-9-08; 8:45 am]
BILLING CODE 4150-31-P